About this site
This is an independent medical information site about daraxonrasib (RMC-6236, brand name RASONQUE). Its aim is to organise, in multiple languages, the drug's mechanism of action, clinical studies, regulatory progress and safety information for healthcare professionals, patients and their families, and industry researchers.
This site has no affiliation with, sponsorship from, or commercial relationship to Revolution Medicines, Inc. or any pharmaceutical company. RASONQUE and other product names are trademarks of their respective owners.
Sources
- U.S. FDA drug approval notices and prescribing information;
- Revolution Medicines press releases and investor disclosures;
- Research articles published in peer-reviewed journals such as the New England Journal of Medicine;
- Public presentations at ASCO, ESMO, AACR and other congresses;
- Trial registrations on ClinicalTrials.gov.
Disclaimer
- Content on this site is for informational purposes only and does not constitute medical advice, diagnosis or treatment, nor does it replace the professional judgement of a physician.
- Indications, dosing, contraindications and adverse reaction information are governed by the latest prescribing information approved by the relevant regulatory authority.
- We strive for accuracy and timeliness, but medical research moves quickly and no guarantee is made as to the completeness or currency of the information.
- This site does not sell medicines, arrange purchases or provide any form of commercial promotion.
- Any consequences arising from the use of information on this site are the sole responsibility of the user.
About translations
This site is authored in Simplified Chinese; other language versions are translations. Where versions differ, the Simplified Chinese version prevails, and drug information is governed by the original English regulatory documents.
Updates
Content is revised as public information evolves, and the date of last review is shown at the bottom of each page. If you spot an error or would like to suggest additional information, please contact us via the email address in the footer.